CytoMed Therapeutics Ltd.
GDTC
CytoMed Therapeutics Ltd. is a Singapore-based biopharmaceutical company focused on developing cell-based immunotherapies for cancer and other serious diseases. Its current pipeline centers on innate immune cell and stem cell-based technologies, including gamma delta T-cell, natural killer T-cell, and pluripotent stem cell platforms designed to support novel therapeutic candidates. The company’s work includes research, development, processing, and banking of cells, with an emphasis on allogeneic approaches that use donor-derived materials. CytoMed Therapeutics Ltd. operates primarily in Singapore and Malaysia, serving the growing biotechnology and advanced therapy markets in Asia. Its role in the financial market is tied to the high-potential but research-intensive biopharmaceutical sector, where progress depends on clinical development, regulatory milestones, and platform innovation.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
SGD 324K
▲ +366.7% YoY
Net Income (TTM)
-SGD 4M
▼ -58.5% YoY
Op. Margin
-1307.60%
▲ +3196.7pp YoY
ROIC
-39.79%
▼ -16.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-SGD 4M
▼ -4.7% YoY
Op. Cash Flow (TTM)
-SGD 4M
▼ -36.4% YoY
Net Debt
-SGD 2M
Net Cash Position
Cash & Equiv.
SGD 2M
Continue Research
Peers
Biotechnology · Pick stocks to compare with GDTC
CytoMed Therapeutics (GDTC) in four numbers
Questions about CytoMed Therapeutics
Is CytoMed Therapeutics (GDTC) overvalued?
At $0.77, CytoMed Therapeutics' price is 1231% above the $0.06 a share fair value that Intrinsiqq's calculator gets from its revenue. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.
What is CytoMed Therapeutics' fair value?
Intrinsiqq's calculator puts CytoMed Therapeutics' fair value at $0.06 a share. It grows revenue per share 5% a year for 5 years, applies an exit P/S of 3.1, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $0.04. Every input can be changed on the Intrinsic Value tab.
Is CytoMed Therapeutics a high-quality business?
CytoMed Therapeutics scores 18 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is net debt at -$2M, and its weakest is return on capital at -39.8%. The Quality tab shows every check against its target.
Does CytoMed Therapeutics (GDTC) pay a dividend?
No. CytoMed Therapeutics (GDTC) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 16 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing GDTC
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.